The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer

ConclusionsMild-to-moderate hepatic or renal dysfunction had no clinically meaningful impact on the pharmacokinetics of panitumumab in patients with mCRC. No dose adjustments for panitumumab are warranted in patients with mCRC with mild-to-moderate hepatic or renal dysfunction.Trial registrationClinicalTrials.gov; NCT00083616, NCT00089635, NCT00113763
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research